Sphingolipids, Diabetes, and Cardiovascular Disease

鞘脂、糖尿病和心血管疾病

• 批准号: 9109632
• 负责人: Rozenn Lemaitre
• 金额: $ 47.74万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-30 至 2018-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9109632
• 关键词: American Indians; Animals; Apoptosis; Atherosclerosis; Biological; Biological Markers; Biology; Carbon; Cardiovascular Diseases; Cardiovascular system; Cells; Ceramides; Communities; Data; Development; Diabetes Mellitus; Diet; Disease; Environmental Risk Factor; Epidemic; Exhibits; Family; Family Study; Fasting; Fatty Acids; Functional disorder; Future; Health; Heart; Hemoglobin; High Prevalence; Human; Incidence; Insulin; Insulin Resistance; Intervention; Ischemic Stroke; Knowledge; Lipids; Measures; Membrane; Metabolic; Metabolic Diseases; Metabolism; Modeling; Morbidity - disease rate; Myocardial Infarction; Non-Insulin-Dependent Diabetes Mellitus; Obesity; Palmitic Acids; Participant; Pathway interactions; Pharmaceutical Preparations; Phospholipids; Physical activity; Physiological; Plasma; Population; Prevention; Process; Prospective Studies; Public Health; Risk; Risk Factors; Sampling; Saturated Fatty Acids; Spectrometry; Sphingolipids; Sphingomyelins; Time; Tobacco; Tribes; Vertebral column; base; blood glucose regulation; diabetes risk; fasting glucose; fighting; follow-up; glucose transport; high risk; improved; insight; insulin sensitivity; insulin signaling; mortality; new therapeutic target; novel; pi bond; prospective; research study; response

DESCRIPTION (provided by applicant): Type 2 diabetes has reached epidemic proportions world-wide and carries a high burden of cardiovascular morbidity and mortality. This application seeks to identify novel modifiable factors, namely plasma ceramide and sphingomyelin species, associated with risks of incident diabetes and cardiovascular disease. Ceramides and sphingomyelins are lipids ("sphingolipids") that influence metabolic processes implicated in the pathophysiology of diabetes and cardiovascular diseases, including apoptosis, lipotoxicity, insulin resistance, glucose homeostasis and atherosclerosis. Until recently, all sphingolipids were thought to have similar physiological effects; however, there is now compelling evidence that sphingolipid species that carry different saturated fatty acids exhibit vastly different biological activities. We propose for the first time to examine the association of specific circulating ceramide and sphingomyelin species with incident diabetes and diabetes-related cardiovascular disease. We hypothesize that plasma ceramide and sphingomyelin species that contain the saturated fatty acid palmitic acid (16:0) are associated with higher risks of incident diabetes and diabetes-related cardiovascular disease. In contrast, we hypothesize that plasma ceramide and sphingomyelin species that contain a saturated fatty acid with 20 or more carbons (20:0, 22:0 or 24:0) are associated with lower risks of incident diabetes and cardiovascular disease. We will investigate these hypotheses in the Strong Heart Family Study, a community-based, prospective study of risk factors for cardiovascular disease among American Indians from 13 different tribes. Because of the high incidence of diabetes and early cardiovascular disease, prospectively studying the association of sphingolipid species with diabetes and cardiovascular disease among American Indians may reveal important mechanistic insights as to the pathways and processes involved. Using state-of-the-art spectrometry, we will measure 8 ceramide and sphingomyelin species in plasma from existing baseline samples from 3665 Strong Heart Family Study participants, and combine these new data with existing information on risk factors and follow- up data to examine the following specific aims: (Aim 1) To prospectively examine the associations of ceramides and sphingomyelins containing the fatty acids 16:0, 20:0, 22:0 and 24:0 with incident diabetes, and changes in fasting glucose, fasting insulin, HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) and hemoglobin A1C among participants without diabetes at baseline; and (Aim 2) To prospectively examine the associations of these sphingolipids with incident diabetes-related cardiovascular disease (including myocardial infarction, ischemic stroke, and cardiovascular mortality). The discovery of precise sphingolipid species associated with diabetes and its cardiovascular complications will point to the potentially causal pathways that need to be targeted for future interventions.

描述（由申请人提供）：2型糖尿病已在世界范围内达到流行比例，并带来心血管发病率和死亡率的高负担。本申请旨在鉴定与糖尿病和心血管疾病风险相关的新的可改变因素，即血浆神经酰胺和鞘磷脂物质。神经酰胺和鞘磷脂是脂质（“鞘脂”），其影响糖尿病和心血管疾病的病理生理学中涉及的代谢过程，包括细胞凋亡、脂毒性、胰岛素抗性、葡萄糖稳态和动脉粥样硬化。直到最近，所有鞘脂都被认为具有相似的生理作用;然而，现在有令人信服的证据表明，携带不同饱和脂肪酸的鞘脂物种表现出截然不同的生物活性。我们首次提出研究特定循环神经酰胺和鞘磷脂与糖尿病和糖尿病相关心血管疾病的关系。我们假设血浆中含有饱和脂肪酸棕榈酸（16：0）的神经酰胺和鞘磷脂与糖尿病和糖尿病相关心血管疾病的发病风险较高相关。相比之下，我们假设血浆神经酰胺和鞘磷脂含有20个或更多碳（20：0，22：0或24：0）的饱和脂肪酸，与糖尿病和心血管疾病的发病风险较低相关。我们将在强心家族研究中调查这些假设，这是一项以社区为基础的前瞻性研究，研究来自13个不同部落的美洲印第安人心血管疾病的危险因素。由于糖尿病和早期心血管疾病的高发病率，前瞻性研究鞘脂物种与美国印第安人糖尿病和心血管疾病的关联可能会揭示有关途径和过程的重要机制见解。使用最先进的光谱法，我们将测量来自3665名强心脏家族研究参与者的现有基线样本的血浆中的8种神经酰胺和鞘磷脂物质，并将这些新数据与风险因素和随访数据的现有信息联合收割机结合，以检查以下特定目的：（目的1）前瞻性检查含有脂肪酸16：0、20：0、22：1的神经酰胺和鞘磷脂的相关性。0和24：0与糖尿病并发症，以及基线时无糖尿病的参与者中空腹血糖、空腹胰岛素、HOMA-IR（胰岛素抵抗稳态模型评估）和血红蛋白A1 C的变化;（目的2）前瞻性检查这些鞘脂与糖尿病相关心血管疾病（包括心肌梗死、缺血性卒中和心血管死亡率）并发症的相关性。与糖尿病及其心血管并发症相关的精确鞘脂种类的发现将指出未来干预措施需要针对的潜在因果途径。